

## Statement of Advice:

**adalimumab (Humira®)**

**(No: 824/12)**

**Abbott Laboratories**

05 October 2012

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation

**adalimumab (Humira®)** is not recommended for use within NHS Scotland.

**Indication under review:** treatment of moderately active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Adalimumab remains a treatment option for adults with severe active Crohn's disease whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy, in line with the [NICE \(Multiple\) Technology Appraisal Guidance No 187](#). Healthcare Improvement Scotland advises that the recommendations are as valid for Scotland as for England and Wales.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman,  
Scottish Medicines Consortium**